Department of Medicine, CURE Digestive Diseases Research Center and Center for Neurobiology of Stress, Digestive Diseases Division UCLA, and VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA.
Obes Rev. 2011 Apr;12(4):261-71. doi: 10.1111/j.1467-789X.2010.00770.x.
The protein nucleobindin 2 (NUCB2) or NEFA (DNA binding/EF-hand/acidic amino acid rich region) was identified over a decade ago and implicated in intracellular processes. New developments came with the report that post-translational processing of hypothalamic NUCB2 may result in nesfatin-1, nesfatin-2 and nesfatin-3 and convergent studies showing that nesfatin-1 and full length NUCB2 injected in the brain potently inhibit the dark phase food intake in rodents including leptin receptor deficient Zucker rats. Nesfatin-1 also reduces body weight gain, suggesting a role as a new anorexigenic factor and modulator of energy balance. In light of the obesity epidemic and its associated diseases, underlying new mechanisms regulating food intake may be promising targets in the drug treatment of obese patients particularly as the vast majority of them display reduced leptin sensitivity or leptin resistance while nesfatin-1's mechanism of action is leptin independent. Although much progress on the localization of NUCB2/nesfatin-1 in the brain and periphery as well as on the understanding of nesfatin-1's anorexic effect have been achieved during the past three years, several important mechanisms have yet to be unraveled such as the identification of the nesfatin-1 receptor and the regulation of NUCB2 processing and nesfatin-1 release.
十多年前,人们发现了核结合蛋白 2(NUCB2)或 NEFA(DNA 结合/EF 手/酸性氨基酸丰富区),并认为其与细胞内过程有关。新的发展是由于报告表明,下丘脑 NUCB2 的翻译后加工可能导致 nesfatin-1、nesfatin-2 和 nesfatin-3,而趋同研究表明,nesfatin-1 和全长 NUCB2 注射到大脑中可有效抑制包括瘦素受体缺乏型 Zucker 大鼠在内的啮齿动物的暗期摄食。nesfatin-1 还可降低体重增加,表明其作为一种新的厌食因子和能量平衡调节剂的作用。鉴于肥胖症的流行及其相关疾病,调节食物摄入的潜在新机制可能成为肥胖患者药物治疗的有希望的靶点,特别是因为绝大多数肥胖患者表现出瘦素敏感性降低或瘦素抵抗,而 nesfatin-1 的作用机制与瘦素无关。尽管在过去三年中,人们在脑和外周组织中 NUCB2/nesfatin-1 的定位以及 nesfatin-1 的厌食作用方面取得了许多进展,但仍有几个重要的机制尚未阐明,例如 nesfatin-1 受体的鉴定以及 NUCB2 加工和 nesfatin-1 释放的调节。